Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare effects of combinations of standard and intensive treatment of glycemia and either blood pressure (BP) or lipids in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. RESEARCH DESIGN AND METHODS: ACCORD enrolled 10,251 type 2 diabetes patients aged 40–79 years at high risk for cardiovascular disease (CVD) events. Participants were randomly assigned to hemoglobin A1c goals of <6.0% (<42 mmol/mol; intensive glycemia) or 7.0–7.9% (53–63 mmol/mol; standard glycemia) and then randomized a second time to either 1) systolic BP goals of <120 mmHg (intensive BP) or <140 mmHg (standard BP) or 2) simvastatin plus fenofibrate (intensive lipid) or simvastatin plus placebo (standard lipid). Proportional hazards models were used to assess combinations of treatment assignments on the composite primary (deaths due to CVD, nonfatal myocardial infarction [MI], and nonfatal stroke) and secondary outcomes. RESULTS: In the BP trial, risk of the primary outcome was lower in the groups intensively treated for glycemia (hazard ratio [HR] 0.67; 95% CI 0.50–0.91), BP (HR 0.74; 95% CI 0.55–1.00), or both (HR 0.71; 95% CI 0.52–0.96) compared with combined standard BP and glycemia treatment. For secondary outcomes, MI was significantly reduced by intensive glycemia treatment and stroke by intensive BP treatment; most other HRs were neutral or favored intensive treatment groups. In the lipid trial, the general pattern of results showed no evidence of benefit of intensive regimens (whether single or combined) compared with combined standard lipid and glycemia treatment. The mortality HR was 1.33 (95% CI 1.02–1.74) in the standard lipid/intensive glycemia group compared with the standard lipid/standard glycemia group. CONCLUSIONS: In the ACCORD BP trial, compared with combined standard treatment, intensive BP or intensive glycemia treatment alone improved major CVD outcomes, without additional benefit from combining the two. In the ACCORD lipid trial, neither intensive lipid nor glycemia treatment produced an overall benefit, but intensive glycemia treatment increased mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, SBP >140 mmHg or <120 mmHg were related to higher risk of adverse renal outcomes in patients with diabetes when compared with those without diabetes and with high CV risk.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“The Steno-2 study showed a major reduction in CVD events and mortality with multifactorial intensive treatment (5,6).”
BackgroundStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 1×
“and dysglycemia, high blood pressure (BP), and dyslipidemia mediate much of this increased CVD risk (1).”
BackgroundEffects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465 · cited 1×
“The Steno-2 study showed a major reduction in CVD events and mortality with multifactorial intensive treatment (5,6).”
BackgroundNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Cited by
Items 101–200 of 263
Yannoutsos, A., Bahous, S. A., Safar, M. E., & Blacher, J. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001665 · Cited by 18
Aronow, W. S. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07605 · Cited by 18
Bress, A. P., Tanner, R. M., Hess, R., Gidding, S. S., Colantonio, L. D., Shimbo, D., & Muntner, P. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003547 · Cited by 17
Burggraaf, B., & Cabezas, M. C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.04.017 · Cited by 18
The optimal blood pressure target in diabetes mellitus: a quest coming to an end?
Papadopoulou, E., Angeloudi, E., Karras, S. Ν., & Sarafidis, P. A. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0079-5 · Cited by 17
Optimal medical treatment of hypertension in patients with coronary artery disease
Mahtta, D., Elgendy, I. Y., & Pepine, C. J. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1534069 · Cited by 17
Bundy, J. D., Mills, K. T., & He, J. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0980-5 · Cited by 17
Österreichischer Blutdruckkonsens 2019
Hypertensiologie, Ö. G. F., Weber, T., Atherosklerosegesellschaft, Ö., Gesellschaft, Ö. D., Angiologie, Ö. G. F. I., Nephrologie, Ö. G. F., Gesellschaft, Ö. K., Neurologie, Ö. G. F., Schlaganfall-Gesellschaft, Ö., Allgemeinmedizin, Ö. G. F., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01565-0 · Cited by 18
Target Blood Pressure for Treatment: Should Current Recommendations Be Changed?
Rosei, E. A. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07469 · Cited by 15
Blood pressure targets for hypertension in patients with type 2 diabetes
Aronow, W. S., & Shamliyan, T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.36 · Cited by 18
Pan, C., Wang, S., Xu, C., & Song, E. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0377-7 · Cited by 17
Weinrauch, L. A., D’Elia, J. A., Finn, P. V., Lewis, E. F., Desai, A. S., Claggett, B. L., Cooper, M. E., & McGill, J. B. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.021 · Cited by 14
Green, M., Shah, B. R., Slater, M. B., Khan, S., Jones, C. R., & Walker, J. D. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191039 · Cited by 14
Dungan, K. M., Craven, T. E., Soe, K. K., Wright, J. T., Basile, J., Haley, W. E., Kressin, N. R., Rani, U., Tamariz, L. J., Whittle, J., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13127 · Cited by 13
Drug treatment of hypertension in older patients with diabetes mellitus
Yandrapalli, S., Pal, S., Nabors, C. C., & Aronow, W. S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1456529 · Cited by 15
Kamishima, K., Ogawa, H., Jujo, K., Yamaguchi, J., & Hagiwara, N. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.01.031 · Cited by 13
Shi, S., Gouskova, N., Najafzadeh, M., Wei, L., & Kim, D. H. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050335 · Cited by 13
Should blood pressure goal be individualized in hypertensive patients?
Yannoutsos, A., Fekih, R. E., Halimi, J., Safar, M. E., & Blacher, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.037 · Cited by 14
Heart Failure Primary Prevention: What Does SPRINT Add?: Recent Advances in Hypertension
Raby, K., Rocco, M. V., Oparil, S., Gilbert, O. N., & Upadhya, B. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.16503 · Cited by 13
Shah, S., Yeheskel, A., Hossain, A. K. M. M., Kerr, J., Young, K., Shakik, S., Nichols, J., & Yu, C. H. Y. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.03.004 · Cited by 13
Pharmacological Management of Diabetic Nephropathy
Papademetriou, V., Alataki, S., Stavropoulos, K., Papadopoulos, C. E., Bakogiannis, K., & Tsioufis, K. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190405164749 · Cited by 14
More Versus Less Blood Pressure Lowering: An Update
Atkins, E. R., & Rodgers, A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.08.007 · Cited by 12
Ren, Y., Zuo, Y., Wang, A., Chen, S., Tian, X., Li, H., He, Y. L., Wu, S., & Ma, C. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14246 · Cited by 12
Contemporary Drug Treatment of Hypertension: Focus on Recent Guidelines
Aronow, W. S., & Frishman, W. H. (2018) · Drugs · doi:10.1007/s40265-018-0887-5 · Cited by 12
Reevaluating the Evidence for Blood Pressure Targets in Type 2 Diabetes
Lamprea-Montealegre, J. A., & de Boer, I. H. (2018) · Diabetes Care · doi:10.2337/dci17-0063 · Cited by 11
Blood Pressure Control and Cardiovascular/Renal Outcomes
Dojki, F. K., & Bakris, G. L. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.008 · Cited by 14
Tsur, N., Menashe, I., & Haviv, Y. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-46919-w · Cited by 13
Bae, J. C., Min, K. W., Kim, Y. H., Kim, K., Hong, E., Park, C., Han, S. Y., & Cha, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13491 · Cited by 12
Health outcomes in diabetics measured with Minnesota Community Measurement quality metrics
Takahashi, P. Y., Sauver, J. L. S., Rutten, L. F., Jacobson, R. M., Jacobson, D., McGree, M., & Ebbert, J. O. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s71726 · Cited by 11
Treatment of Hypertension in Patients with Diabetes Mellitus: a Contemporary Approach
Alencherry, B., & Laffin, L. J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01443-0 · Cited by 11
Wang, X., Zheng, K., Hu, X., & Pei, J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112163 · Cited by 12
Capítulo 10 - Hipertensão na Criança e no Adolescente
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160160 · Cited by 10
Yang, R., Bai, J., Fang, Z., Wang, Y., Feng, Y., Liu, Y., Chi, H., Deng, Y., Song, Q., & Cai, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14927 · Cited by 10
Hypertension Management in Chronic Kidney Disease and Diabetes
Thomas, G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.04.006 · Cited by 11
The 2017 U.S. Hypertension Guidelines: What Is Important for Older Adults?
Cushman, W. C., & Johnson, K. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15395 · Cited by 9
Self-citationPlasma metabolites mediate the effect of HbA1c on incident cardiovascular disease
Dong, X., Zhou, W., Li, H., Fan, Y., Yin, X., Li, Y., Chen, F., & Ma, G. (2019) · Clinical Cardiology · doi:10.1002/clc.23243 · Cited by 14
Prediction of transient ischemic attack and minor stroke in people with type 2 diabetes mellitus
Isaman, D. J. M., Herman, W. H., & Ye, W. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107911 · Cited by 10
Rehman, H., Akeroyd, J. M., Ramsey, D. J., Ahmed, S. T., Merchant, A. T., Navaneethan, S. D., Petersen, L. A., & Virani, S. S. (2017) · Clinical Cardiology · doi:10.1002/clc.22769 · Cited by 9
Vargas‐Uricoechea, H., & Cáceres-Acosta, M. F. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.07.001 · Cited by 10
Choi, W., Lee, H. S., Hong, J. H., Chang, H., & Lee, J. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16245134 · Cited by 9
Interpreting SPRINT: How low should you go?
Thomas, G., Nally, J. V., & Pohl, M. A. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83a.15175 · Cited by 8
Vargas‐Uricoechea, H., & Cáceres-Acosta, M. F. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2018.12.001 · Cited by 13
Clinical Update on Nursing Home Medicine: 2014
Messinger‐Rapport, B. J., Gammack, J. K., Little, M. O., & Morley, J. E. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.09.001 · Cited by 9
Kidney, R. S. M., Peacock, J. M., & Smith, S. A. (2014) · PubMed Central · doi:10.5888/pcd11.140204 · Cited by 8
Managing the elderly patient with hypertension: current strategies, challenges, and considerations
Aronow, W. S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1732206 · Cited by 8
Aronow, W. S. (2019) · Minerva Cardioangiologica · doi:10.23736/s0026-4725.19.04965-x · Cited by 9
Stergiou, G. S., Doumas, M. N., Κόλλιας, Α., & Papademetriou, V. (2016) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2016.06.002 · Cited by 8
BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?
Bhatt, H., Ghazi, L., Calhoun, D. A., & Oparil, S. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0775-0 · Cited by 7
Capítulo 5 - Decisão e Metas Terapêuticas
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160155 · Cited by 10
Xu, H., Gu, X., Tadesse, M. G., & Balasubramanian, R. (2018) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.2018.1474115 · Cited by 7
Joint testing of overall and simple effects for the two-by-two factorial trial design
Leifer, E., Troendle, J. F., Kolecki, A., & Follmann, D. A. (2021) · Clinical Trials · doi:10.1177/17407745211014493 · Cited by 8
Managing Hypertension in the Elderly: What is Different, What is the Same?
Aronow, W. S. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0764-8 · Cited by 7
Olsen, E., Søraas, C. L., Schmieder, R. E., Jamerson, K., MacDonald, T. M., Mancia, G., Heimark, S., Mehlum, M. H., Liestøl, K., Larstorp, A. C. K., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf093 · Cited by 6
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
Wokhlu, A., Smith, S. M., Gong, Y., Handberg, E. M., Elgendy, I. Y., Bavry, A. A., Cooper‐DeHoff, R. M., & Pepine, C. J. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001559 · Cited by 6
Tan, S., Goudot, G., Arnoux, A., Tran, Y., Maissoro, H., Poénou, G., Detriche, G., Khider, L., Mohamedi, N., Mirault, T., et al. (2022) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2022.09.064 · Cited by 6
Wang, S., Khera, R., Das, S. R., Vigen, R., Wang, T., Luo, X., Lü, R., Zhan, X., Xiao, G., Vongpatanasin, W., et al. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.03.361 · Cited by 6
Laffin, L. J., & Bakris, G. L. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13249 · Cited by 6
Why Have the Complications of Diabetes Mellitus Declined Over the Past 30 Years?
Morley, J. E. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.04.022 · Cited by 5
Implications of the New National Guidelines for Hypertension
Aronow, W. S., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000187 · Cited by 5
Overt hypogonadism is a cardiovascular risk factor in type 2 diabetic males: An observational study
Oğuz, A., Şahin, M., Ülgen, C., Uyan, M., & Gül, K. (2021) · Andrologia · doi:10.1111/and.14271 · Cited by 5
Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024
Abrahams, T., Nicholls, S. J., & Nelson, A. J. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.12.005 · Cited by 5
Aldafas, R., Crabtree, T. S. J., Vinogradova, Y., Gordon, J. P., & IDRIS, I. R. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2166489 · Cited by 7
Blood Pressure–Related Outcomes in a Diabetic Population
Whaley‐Connell, A. T., & Sowers, J. R. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07439 · Cited by 5
Optimizing Medical Management in Patients with Sight-Threatening Diabetic Retinopathy
Mamtora, S., Sandinha, T., Carey, P. E., & STEEL, D. H. (2016) · Ophthalmology and Therapy · doi:10.1007/s40123-016-0069-z · Cited by 5
Gong, Y., Smith, S. M., Handberg, E. M., Pepine, C. J., & Cooper‐DeHoff, R. M. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13247 · Cited by 5
Blood pressure: at what level is treatment worthwhile?
Atkins, E., & Perkovic, V. (2019) · Australian Prescriber · doi:10.18773/austprescr.2019.038 · Cited by 5
Niakan, A., & Cushman, W. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95800-8 · Cited by 5
Self-citationWhat should the target blood pressure goals be?
Aronow, W. S. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.62916 · Cited by 4
Kiyohara, K., Kondo, N., Iwami, T., Yano, Y., Nishiyama, A., Node, K., Inagaki, N., Duru, O. K., & Inoue, K. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033860 · Cited by 4
Fukunaga, N., Tamakoshi, K., & Hayashi, T. (2022) · Japan Journal of Nursing Science · doi:10.1111/jjns.12517 · Cited by 4
Yang, R., Wang, Y., Tong, A., Yu, J., Zhao, D., & Cai, J. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.04.019 · Cited by 5
Li, W., Wang, Z., Li, M., Jiang, C., Hua, C., Tang, Y., Zhang, H., Liu, X., Zheng, S., Guo, H., et al. (2025) · Heart · doi:10.1136/heartjnl-2024-324360 · Cited by 4
Mousavi, A., Shojaei, S., Abhari, A. P., Mirhosseini, S. A., Ebrahimi, R., Rajabi, E., Farooqi, M. A., Azizpour, A., Moghadam, S. A., Kuno, T., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf140 · Cited by 4
Yamada, M. H., Fujihara, K., OSAWA, T., Yamamoto, M., Kaneko, M., Ishizawa, M., Matsubayashi, Y., Yamada, T., YAMANAKA, N., Seida, H., et al. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.009 · Cited by 4
Hypertension and Cardiovascular Disease in Patients with Chronic Kidney Disease
Hamrahian, S. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-83082-3_15 · Cited by 5
Yu, L., Dong, F., Li, Y., Yang, W., Wu, S., Shan, Z., Teng, W., & Zhang, B. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i32.11789 · Cited by 4
Olsen, E., Mariampillai, J. E., Schmieder, R. E., Jamerson, K., Søraas, C. L., Mancia, G., Mehlum, M. H., Liestøl, K., Larstorp, A. C. K., Halvorsen, L. V., et al. (2025) · Blood Pressure · doi:10.1080/08037051.2025.2544715 · Cited by 3
Pervyshin, N. A. (2025) · Russian Open Medical Journal · doi:10.15275/rusomj.2025.0314 · Cited by 3
What is the most appropriate target SBP in persons with hypertension and diabetes mellitus?
Ahmad, A., & Oparil, S. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001603 · Cited by 3
Wang, Z., Wang, J., He, L., Jiang, C., Wang, Y., Shen, T., Zhao, M., Li, E., Zhou, N., Sang, C., et al. (2025) · Journal of Clinical Hypertension · doi:10.1111/jch.70095 · Cited by 3
Schernthaner, G., Saely, C. H., Schernthaner, G.-H., Watschinger, B., & Drexel, H. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1460-2 · Cited by 3
Cardiovascular Disease in Patients with Diabetes: A Comparison of Professional Society Guidelines
Sarkar, S., Salazar, I. M. C., Tibuakuu, M., & Blumenthal, R. S. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210820105514 · Cited by 3
Managing Hypertension in the Elderly: What is Different, What is the Same?
Aronow, W. S. (2017) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-017-0548-3 · Cited by 3
Intensive lowering of blood pressure: Should we SPRINT?
Rabi, D. M., & Padwal, R. S. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.160147 · Cited by 3
Hypertension Treatment in Diabetes
Bensimhon, H. F., & Cavender, M. A. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.008 · Cited by 4
Manejo da hipertensão arterial no diabetes
Izar, M. C. D. O., Fonseca, F. A. H., Faludi, A. Á., de Araújo, D. B., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-16 · Cited by 5
Dasa, O., Smith, S. M., & Pepine, C. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00033-5 · Cited by 4
Buckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Tassell, B. W. V. (2018) · Diabetes Care · doi:10.2337/dci17-0066 · Cited by 3
Fallahtafti, P., Semirani-Nezhad, D., Maleki, S., Zafarmandi, S., Dastjerdi, P., Rahmati, S., Roozbehi, K., Shaker, F., Fekri, M., Nanna, M. G., et al. (2025) · American Journal of Nephrology · doi:10.1159/000547812 · Cited by 2
Cardiovascular Risk Factors: Hypertension
Nilsson, P. M. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch42 · Cited by 2
Hypertension and Chronic Kidney Disease Including Dialysis
Dhaybi, O. A., & Bakris, G. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00035-9 · Cited by 2
Blood Pressure–Lowering Targets in Patients With Diabetes Mellitus
Leung, A. A. C., & Padwal, R. S. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.10.024 · Cited by 3
Secondary Prevention of Coronary Artery Disease
Watson, K. E., Guo, Y., & Sahni, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00030-3 · Cited by 3
Pineda, C. L. F., Suárez, F. C., Ochoa, A., Rengifo-Quintero, L. J., & Isaza, J. R. (2018) · Acta Médica Colombiana · doi:10.36104/amc.2018.970 · Cited by 2
Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It?
Sarafidis, P. A., & Bakris, G. L. (2020) · Diabetes Care · doi:10.2337/dci20-0019 · Cited by 2
Prevalence of coronary risk factors in load transport drivers
Braga, B. B., Ferreira, F. G., Reis, H. H. T., & Marins, J. C. B. (2022) · Revista Brasileira de Medicina do Trabalho · doi:10.47626/1679-4435-2022-695 · Cited by 2
Lee, D., Huang, C., Yeh, W., Sung, S., Chen, C., & Cheng, H. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000840 · Cited by 2
Cardiovascular Autonomic Neuropathy
Ang, L. P., & Pop‐Busui, R. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_12 · Cited by 2
Modern aspects of the treatment of patients with arterial hypertension and coronary heart disease
Бондарчук, С. А., & Andrievsky, О. G. (2020) · Medicine of Ukraine · doi:10.37987/1997-9894.2020.1(237).214171 · Cited by 1
Metadata
- Authors
- Margolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., Lipkin, E. W., Narayan, K. M. V., Riddle, M. C., Sood, A., & Goff, D. C.
- Affiliations
- HealthPartners (US)
- Wake Forest University Health Sciences (US)
- University of North Carolina at Chapel Hill (US)
- Cincinnati VA Medical Center (US)
- Memphis VA Medical Center (US)
- National Heart, Lung, and Blood Institute (US)
- McMaster University (CA)
- Berman Center for Outcomes and Clinical Research (US)
- University of Washington (US)
- Emory University (US)
- Oregon Health & Science University (US)
- Louis Stokes Cleveland VA Medical Center (US)
- Colorado School of Public Health (US)
- Corresponding author
- Margolis, Karen L.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-05-10
- Volume
- 37
- Issue
- 6
- Pages
- 1721-1728
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4030092
- OpenAlex
- W2167872811
- Cited by
- 259
- References
- 29
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 12 · 2021: 18 · 2020: 19 · 2019: 31 · 2018: 54 · 2017: 32 · 2016: 39 · 2015: 7 · 2014: 5
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- type 2 diabetes, cardiovascular risk management, tight glycemic control, HbA1c, blood pressure control, lipid-lowering therapy, simvastatin, fenofibrate, cardiovascular outcomes, myocardial infarction, stroke, mortality, ACCORD trial, combination therapy, cardiovascular risk reduction, high-risk patients, secondary prevention, primary prevention, cardiovascular risk stratification
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Myocardial Infarction, Outcome and Process Assessment, Health Care, Fenofibrate, Risk Factors, Disease Management, Simvastatin, Stroke, Risk Reduction Behavior, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.